Moderna, Inc. (MRNA) Stock Price & How to Invest

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

The investment picture is a classic biotech turnaround. Q1 2026 revenue was roughly $400 million, up meaningfully year over year but tiny next to the pandemic peak, and the company posted a large net loss (heavily inflated by an ~$878 million legal settlement charge). Management guides to up to 10% revenue growth in 2026 and a cash flow break-even target by 2028, backed by a multibillion-dollar cash cushion. That leaves MRNA valued far more on future pipeline outcomes (flu approval, combination shots, and cancer-vaccine data) than on trailing financials, which is why the stock is volatile and closely tied to clinical and regulatory headlines.

Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed.

19 analysts publish price targets on MRNA, averaging $49.47 against a $54.82 price as of August 2026, or -9.8%. The published targets run from $25.00 to $79.00, a wide spread, and the ratings split 4 buy, 16 hold, 3 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MRNA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Moderna, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Respiratory franchise beyond COVID. Moderna is trying to convert a single-product COVID business into a broader respiratory portfolio. The most optimistic published target, $79.00, assumes this works close to its best case.

The case against. Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The most pessimistic target, $25.00, is roughly what MRNA is worth if this bites instead.

Read the full bull and bear case on MRNA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Moderna, Inc.'s investor relations page or your broker.

• Market cap: ~$20 billion
• Q1 2026 revenue: ~$400 million
• Q1 2026 net loss: ~$1.3 billion (incl. ~$878M legal charge)
• 2026 revenue growth guidance: up to ~10%
• Cash and investments: ~$7.5 billion (end of Q1 2026)
• Break-even target: cash flow break-even by ~2028

MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.

If you want MRNA exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses MRNA naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to MRNA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MRNA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FBT, XBI, VBR), which spreads the position across many companies. Or build it into a focused thematic portfolio, so MRNA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MRNA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

MRNA is a post-COVID biotech turnaround where the value sits almost entirely in a late-stage pipeline that has not yet proven it can offset shrinking COVID sales.

Whether MRNA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MRNA a buy or a sell?, and where the stock could go from here in the MRNA stock forecast.

For income investors, whether MRNA pays a dividend and how the payout looks is covered in does MRNA pay a dividend? And to weigh MRNA against a peer, read the full side-by-side comparisons: MRNA vs VRTX and MRNA vs REGN.